Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Cytocom submits IND application to conduct Phase II Covid-19 drug trial

pharmaceutical-technologyFebruary 19, 2021

Tag: Cytocom , COVID-19 , CYTO-205

PharmaSources Customer Service